Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
April 13, 2023 09:00 ET
|
Editas Medicine, Inc.
Emma Reeve to support Editas’ evolution in new role as Chair of the Board Elliott Levy, M.D., joins Board as an Independent Director CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE)...
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
March 08, 2023 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Company’s...
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
February 22, 2023 06:15 ET
|
Editas Medicine, Inc.
Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter On track to provide clinical update for RUBY trial by mid-2023 and...
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
February 15, 2023 06:45 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast...
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
January 19, 2023 07:00 ET
|
Editas Medicine, Inc.
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for...
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
January 09, 2023 08:15 ET
|
Editas Medicine, Inc.
Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing Discontinuing internal investments in inherited retinal diseases and in preclinical wholly owned iNK...
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 06:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the Company’s President and CEO Gilmore...
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
December 06, 2022 06:30 ET
|
Editas Medicine, Inc.
EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant Both patients treated with...
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
December 01, 2022 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on, Tuesday,...
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
November 17, 2022 07:15 ET
|
Editas Medicine, Inc.
EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy endpoints seen in homozygous patients ...